Skip to main content
. 2021 Apr;62(4):536–544. doi: 10.2967/jnumed.120.243600

FIGURE 3.

FIGURE 3.

18F-LW223, assessed in naïve rats, has favorable metabolic profile and specifically targets TSPO in vivo. (A) Maximum-intensity projection of 18F-LW223 PET scan in naïve rat showing major uptake organs (left); metabolism of 18F-LW223 within rat blood showing high percentage of parent radiotracer within plasma up to 2 h after injection (middle, n = 3 per time point); and percentage of parent radiotracer within different tissues demonstrating low level of contaminating radiometabolites (right, n = 3). (B) SUV images of rat heart (left), lung (middle), and brain (right) at baseline (left side of each panel) and under TSPO blockade using prototypical TSPO ligand PK11195 (1 mg/kg, right side of each panel) demonstrating specificity of 18F-LW223 for this target. SUV PET images were filtered using gaussian 1 × 1 × 1 mm filter. (C) Total VT within heart (left), lung (middle), and brain (right) of naïve and TSPO-blocked rats. Results represent mean ± SEM (n = 6 for naïve; n = 3 for blocked). P values were obtained using unpaired t test. A = adrenal glands; B = brain; G = gut; H = heart; K = kidney; L = lung. *P < 0.05. **P ≤ 0.01. ***P ≤ 0.001.